Investor's Business Daily on MSN

Biogen clears key benchmark, hitting 80-plus RS rating

Biogen sees its Relative Strength Rating enter the 80-plus level.

Lululemon Set to Exit Nasdaq 100 as Index Adds New Members

Six companies, including Alnylam Pharmaceuticals and Seagate Technology, will join the Nasdaq 100 when the changes take effect later this month. The updates aim to keep the index aligned with the ...

Top catalysts for the Nasdaq 100 Index and key ETFs like QQQ, JEPQ

Here are the top catalysts for the Nasdaq 100 Index and its ETFs, like QQQ and JEPQ, including the upcoming BoJ rate decision ...

Nasdaq-100 Shake-Up: These 6 Stocks Are In, 6 Are Out — And It Could Trigger Big Moves

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...
BioSpace

FDA’s ‘Conundrum’: What To Do With Approved Drugs That Fail Pivotal or Confirmatory Trials

With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...
Opinion

Biogen: Alzheimer's Disease Treatment Needs More Real-World Data

Get insights on Biogen’s Leqembi sales outlook, clinical value, risks, and what new drug approvals may mean for investors.

Bitcoin hoarding company Strategy remains in Nasdaq 100

Dec 12 (Reuters) - Bitcoin hoarding giant Strategy clung to its place in the Nasdaq 100 on Friday, continuing its year-long ...